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The major pulmonary antioxidant enzyme involved in the protection of the lung interstitium from
oxidative stress is extracellular superoxide dismutase (EC-SOD). It has been previously shown that
EC-SOD knock-out mice are more susceptible to bleomycin-induced lung injury, however, the
molecular mechanism(s) remains unclear. We report here that bleomycin-induced lung damage,
in EC-SOD KO mice, is associated with increased hyaluronan release into alveolar ﬂuid. Analysis of
hyaluronan synthase gene expression and hyaluronan molecular weight distribution suggested that
elevated levels of hyaluronan in the alveolar ﬂuid are mostly due to its release from the interstitium.
Our results indicate that EC-SOD attenuates bleomycin-induced pulmonary injury, at least in part,
by preventing superoxide-mediated release of hyaluronan into alveolar space.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Acute lung injury and acute respiratory distress syndrome are
frequent complications in critically ill patients and are major
causes of increased morbidity and mortality. These processes re-
ﬂect severe injury to pulmonary epithelial and endothelial cells
and are due, at least in part, to the generation of excessive levels
of reactive oxygen and nitrogen species [1]. Reactive oxygen spe-
cies (ROS), which include superoxide anion radical, hydrogen per-
oxide and hydroxyl radical, produce cell injury by causing lipid
peroxidation, DNA damage leading to DNA mutations and oxida-
tion of proteins.
The primary defense against excessive production of superoxide
radicals in the lung includes the superoxide dismutase family of
enzymes. There are three mammalian genes that encode cytosolic
(sod1), mitochondrial (sod2) and extracellular (sod3) superoxide
dismutases [2]. The unique localization of extracellular superoxide
dismutase (EC-SOD) to extracellular matrix components, suggests
that it can play an important role in attenuating lung injury caused
by ROS present in the extracellular space. Indeed, mice deﬁcient in
EC-SOD show markedly higher lung inﬂammation, enhanced ﬁbro-chemical Societies. Published by E
OD, extracellular superoxide
isville, 570 S. Preston Street,
States. Fax: +1 502 852 2492.
o).sis and increase in protein fragmentation [3]. Moreover, overex-
pression of EC-SOD in murine lung attenuated the effects of
bleomycin [4]. Intratracheal administration of bleomycin has been
used as a model to study the mechanisms responsible for acute
lung injury and subsequent development of ﬁbrosis. The precise
molecular mechanism of bleomycin-mediated lung injury is not
well understood, but it is believed that bleomycin administration
results in increased production of ROS [5,6].
Hyaluronan is a nonsulfated linear glycosaminoglycan com-
posed of repeated disaccharide units containing glucuronic acid
and n-acetylglucosamine. Hyaluronan plays an important role in
maintaining extracellular matrix integrity and in regulating
intercellular activities [7]. In the healthy lung, hyaluronan exists
as a high molecular weight polymer with an average size of
>2000 kDa [8]. However, during bleomycin-induced acute lung in-
jury, hyaluronan undergoes fragmentation into low molecular
weight species [9]. It is generally accepted that hyaluronan can be
degraded into smaller fragments in one of two ways; by hyaluron-
idase activity or by direct attack from ROS, especially the highly
reactive hydroxyl radical [10]. The appearance of small molecular
weight hyaluronan fragments (not due to ROS) can be attributed
to changes in expression and/or activities of enzymes involved in
its synthesis and catabolism. There are three mammalian hyaluro-
nan synthesizing enzymes characterized to date: HAS1, HAS2 and
HAS3. It has been shown that HAS1 and HAS2 synthesize high
molecular weight hyaluronan, while HAS3 produces shorter
hyaluronan fragments [11]. Hyaluronidases are responsible forlsevier B.V. All rights reserved.
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and Hyal-2) represents majority of hyaluronidase-like activities in
somatic tissues. These enzymes cleaves highmolecular weight hya-
luronan to small fragments of about 50 disaccharide units [12].
In this paper, we report that mice lacking EC-SOD are more sus-
ceptible to bleomycin-induced lung injury. Bleomycin exposure re-
leased EC-SOD from alveolar septa and signiﬁcantly increases
levels of hyaluronan in the broncho alveolar lavage ﬂuid (BALF).
We also show that this increase in hyaluronan concentration is
not attributed to increased synthesis of hyaluronan by hyaluronan
synthases.2. Materials and methods
2.1. ROS-mediated hyaluronan degradation
In vitro ROS were generated using xanthine/xanthine oxidase.
Six micrograms of high molecular mass hyaluronan from human
umbilical cord (Sigma–Aldrich, St. Louis, MO) was added to 50 ll
of PBS containing 300 lM xanthine and 1 U of xanthine oxidase.
The reaction was allowed to proceed for 4 h at 37 C, and the
reaction mixtures were analyzed using 0.6% agarose gel. The
hyaluronan was visualized using Stains-All dye (1-ethyl-2-[3-(1-
ethylnaphtho[1,2-d[thiazolin-2-ylidene)-2-methylpropenyl] naph-
tha[1,2-d] thiazolium bromide (Sigma–Aldrich, St. Louis, MO).
2.2. Bleomycin treatment of mice
All experiments involving animals were approved by the Uni-
versity of Louisville Institutional Animal Care and Use Committee.
Homozygous EC-SOD KO mice (C57BL/6) were generated by
homologous recombination and bred into C57BL/6 background
for more than 10 generations [16]. Control wild-type mice
(C57BL/6) were obtained from Taconic (Germantown, NY). All of
the experiments in this study were performed using 6–8 weeks
old male mice. Mice were given one intratracheal injection of
5 U/kg by weight of bleomycin (Bredford Laboratories, Bedford,
OH) in 20–25 ll of 0.9% saline or an equivalent volume of 0.9% sal-
ine and then sacriﬁced 7 days post-treatment. Mouse lungs were
subjected to bronchoalveolar lavage by intratracheally instilling
and then removing 1 ml of 0.9% saline. Lungs were removed, quick
frozen in liquid nitrogen, and stored at 80 C until further
analysis.
2.3. Extraction of lung tissue hyaluronan
The hyaluronan was extracted from mouse lung as previously
described [8]. Brieﬂy, the perfused mouse lungs were diced into
small pieces and digested with 5 U of protease (Sigma–Aldrich,
St. Louis, MO) in 50 mM Tris–HCl pH 7.5 buffer containing
10 mM CaCl2 overnight at 55 C. The protease was inactivated by
boiling the sample for 10 min. Samples were concentrated with a
centrifugal ﬁlter device (cut off 30 kDa, Millipore).
2.4. Analysis of hyaluronan levels and molecular size in the lung and
BALF
Concentrated lung tissue hyaluronan samples were separated
on 0.6% agarose gel and then transferred onto GeneScreen Plus
membrane (Millipore, Billerica, MA) pretreated with 1% cetylpyri-
dinium chloride. Native hyaluronan was puriﬁed from human
umbilical vein. Sonicated hyaluronan was used as a reference for
it’s molecular size. After transfer, the membrane was blocked over-
night at 4 C in 100 mM sodium acetate, pH 6.0, 1 M NaCl, 0.05%
Tween 20, 2% nonfat dry milk. The hyaluronan was detected usingbiotinylated-hyaluronan-binding protein (ﬁnal concentration
100 ng/ml) and then incubated with streptavidin conjugated to
horseradish peroxidase. The peroxidase activity was visualized by
chemiluminescent detection using the Western Lightning detec-
tion kit and X-ray ﬁlm.
To compare the levels of hyaluronan in BALF from wild-type
and EC-SOD KO mice treated with either saline or bleomycin,
100 ll of BALF were directly applied to GeneScreen Plus membrane
(Millipore, Billerica, MA) pretreated with 1% cetylpyridinium chlo-
ride. The hyaluronan detection was performed as described above.
2.5. Quantiﬁcation of hyaluronan levels
Hyaluronan levels in BALF samples were measured using hyalu-
ronan enzyme-linked immunosorbent assay (Echelon, Salt Lake
City, UT).
2.6. Western blot
ForWestern blot analysis, 20 lg of total BALF were separated on
a 12% SDS/polyacrylamide gel and transferred to an Immobilon-P
membrane (Millipore, Billerica, MA). The membrane was subse-
quently incubated for 1 h at room temperature with rabbit anti-
mouse EC-SOD, diluted 1:200 in 5% nonfat milk, 0.04% Tween 20
in PBS. Anti-mouse EC-SOD (SS618) polyclonal antibodies were de-
scribed previously [13]. Horseradish peroxidase-conjugated goat-
anti rabbit IgG was used as a secondary antibody. The speciﬁc com-
plexes were visualized using enhanced chemiluminescence plus kit
(Amersham, Arlington Heights, IL, USA) according to manufac-
turer’s instructions.
2.7. Quantitative RT-PCR
Total RNA was prepared from mouse tissues using Trizol re-
agent (Invitrogen, Carlsbad, CA). The synthesis of single stranded
DNA from RNA was performed using SuperScript First-Strand Syn-
thesis System for RT-PCR and random hexamers (Invitrogen, Carls-
bad, CA), according to the protocol provided by manufacturer.
Levels of mRNA gene expression were quantiﬁed using the follow-
ing gene speciﬁc primers: HAS1 (forward 50-AGT ATA CCT CGC GCT
CCA GA-30 and reverse 50-AGC AGC AGT AGA GCC CAG AG-30);
HAS2 (forward 50-AAC AGG GTG TTG AGT CTG GG-30 and reverse
50-TAA ACC ACA CGG ACA CTG GA-30); HAS3 (forward 50-CGG
GTG AAG GAG AGA CAG AG-30 and reverse 50-GCA ATG AGG AAG
AAT GGG AA-30); GAPDH (forward 50-CAG CCT CGT CCC GTA GAC
AA-30 and reverse 50- TTT GAT GTT AGT GGG GTC TC-30). The quan-
titative PCR was undertaken using the iCycler iQ™ Real-Time PCR
Detection System (Bio-Rad, Hercules, CA) and a iQ SYBR Green
Master Mix. The PCR cycles were 95 C for 3 min, then 40 cycles
of 95 C for 15 s, 60 C for 1 min. The speciﬁcity of ampliﬁcation
for each pair was conﬁrmed by separation of ampliﬁed fragments
by agarose electrophoresis and by performing melting curve anal-
ysis. PCR assays were run in triplicate.
2.8. Statistical analyses
Statistical analysis was performed using t-test with a P < 0.05
considered signiﬁcant.3. Results and discussion
3.1. EC-SOD protects hyaluronan from degradation by ROS
In order to conﬁrm that ROS produce a low molecular weight
fragment of hyaluronan, we exposed ﬁxed amounts of hyaluronan
Fig. 1. Protective effect of EC-SOD and catalase on hyaluronan fragmentation by
reactive oxygen species (ROS). Xanthine/xanthine oxidase system (X/XO) was used
to generate ROS. Both, EC-SOD (SOD) and catalase (Cat) protect hyaluronan from
fragmentation. The identity of hyaluronan was conﬁrmed by digestion with
hyaluronan lyase. The sonication of hyaluronan leads to accumulation of small
molecular weight fragments.
Fig. 2. EC-SOD protects lung from bleomycin-induced injury. (A) Increased total
protein concentration in bronchoalveolar ﬂuid (BALF) of EC-SOD KO mice treated
with bleomycin. Mice were injected intratracheally with saline or bleomycin and
total protein was measured in BALF samples 7 days following exposure. Results
shown are mean ± S.D.; n = 4 in each group. (B) EC-SOD released into BALF after
bleomycin exposure. Mice were administered saline or bleomycin intratracheally
and BALF was collected 7 days after exposure. Identical amounts of BALF total
protein was loaded in each well prior to separation on 8–15% PAAG gel. After
transfer to PVDF membranes, EC-SOD was detected using rabbit anti-mouse speciﬁc
antibodies. Note the dramatic increase of EC-SOD content in BALF after bleomycin
treatment and the absence of EC-SOD speciﬁc bands in the knock-out mice. Arrow
shows EC-SOD speciﬁc bands.
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duced by xanthine/xanthine oxidase system. This treatment signif-
icantly reduces the average molecular size of hyaluronan polymer
(Fig. 1). To determine the protective role of catalase and EC-SOD in
hyaluronan fragmentation, we exposed hyaluronan to in vitro ROS
generating system in the presence or absence of puriﬁed EC-SOD
and/or catalase. The inclusion of these antioxidant enzymes into
the reaction mixture was found to completely abolish ROS-medi-
ated hyaluronan degradation (Fig. 1). This effect was speciﬁc be-
cause addition of bovine serum albumin to the reaction mixture
did not produce any notable effect. Control treatment of hyaluro-
nan with ultrasound produced fragmentation of the hyaluronan
polymer. Digestion of hyaluronan with hyaluronan lyase, an en-
zyme that produces hyaluronan monomers, resulted in the com-
plete disappearance of hyaluronan-speciﬁc bands on the stained
agarose gel (Fig. 1). These data show that hyaluronan is undergoing
fragmentation by ROS and that EC-SOD and catalase protects it
from degradation.
3.2. Treatment of mice with bleomycin produces lung injury and
release of EC-SOD in BALF
Next, we decided to elucidate the role of EC-SOD in the protec-
tion of hyaluronan from fragmentation, using an in vivo model,
and analyze it’s protective effects on the development of lung in-
jury. We used the bleomycin model of acute lung injury because
it has been shown that bleomycin exerts its lung damaging effectsthrough the generation of ROS. We hypothesized that EC-SOD (and
possibly other antioxidant enzymes) might play a protective role in
bleomycin-induced acute lung injury. For this purpose wild-type
(C57Bl/6) and EC-SOD null mice were treated with bleomycin by
intratracheal injection. One week later mice were sacriﬁced and
brochoalveolar lavage ﬂuid (BALF) samples and lung tissue were
collected for analysis. Bleomycin exposure produced a prominent
increase in the protein concentration in BALF of both groups of mice
(Fig. 2A). However, EC-SOD KO mice showed signiﬁcantly higher
concentration of protein in BALF (1076.88 ± 46.45 lg/ml) compare
to wild-type littermates (965.66 ± 42.13 lg/ml), suggesting that
EC-SOD knock-out mice have enhanced bleomycin-induced lung
injury (Fig. 2A). The statistically signiﬁcant (P < 0.05), but relatively
small difference in BALF protein concentrations between wild-type
and EC-SOD KO mice may be attributed to the high doses of bleo-
mycin used that could overload the protective effects of EC-SOD
in the lungs of wild-type mice.
It has been shown that variety of stresses can induce proteolytic
cleavage of the heparin-binding domain of EC-SOD which can, in
turn, contribute to the loss of enzyme from the extracellular matrix
[14]. Thus, we decided to investigate the effects of bleomycin expo-
sure on EC-SOD levels in BALF. Bleomycin exposure of wild-type
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(Fig. 2B). Interestingly, the EC-SOD present in BALF of bleomycin
treated mice appears to mostly exist in its full-length form. These
data suggest that the release of EC-SOD from the extracellular ma-
trix after bleomycin treatment is not due to proteolytic cleavage.
As expected, mice with disrupted expression of EC-SOD do not
show any EC-SOD speciﬁc bands on the Western blot. These data
indicate that bleomycin produces prominent lung injury and facil-
itates the non-proteolytic release of EC-SOD from the interstitium,
and accumulation in BALF.
3.3. Lack of EC-SOD enhances the accumulation of hyaluronan in the
lung following oxidative stress induced by bleomycin
To investigate the role of hyaluronan in the development of ble-
omycin-induced acute lung injury, we measured BALF hyaluronanFig. 3. Effect of bleomycin on hyaluronan levels in mouse bronchoalveolar ﬂuid (BALF). (A
nitrocellulose membrane. After blocking, the membrane was incubated with hyaluronan
visualized using standard chemiluminescent method. (B) Hyaluronan in BALF samples
bleomycin treatment on hyaluronan molecular weight distribution. Wild-type (WT) and
the lungs were collected and hyaluronan was extracted as described in Section 2. Hya
membranes and detected by Western blot using biotinylated-hyaluronan-binding prote
bleomycin treatment.levels in wild-type and EC-SOD null mice 7 days later following
exposure to either saline or bleomycin. Hyaluronan levels in BALF
were measured using two different methods. First, we used a dot-
blot assay to measure the relative levels of hyaluronan in BALF
samples from our control and bleomycin treated mice. An obvious
increase in hyaluronan levels were observed in both groups of mice
following bleomycin exposure. However, EC-SOD KO mice showed
more prominent increases in hyaluronan compared to wild-type
mice (Fig. 3A). Similar results were seen when we used an ELISA as-
say to quantitate levels of BALF hyaluronan. Exposure to bleomycin
increased hyaluronan levels in BALF of wild-type mice 160.4 fold
(from 10.9 ± 2.7 lg/ml to 1746.5 ± 139.5 lg/ml) and 370.9 fold
(from 8.6 ± 1.9 lg/ml to 3171.2 ± 246.7 lg/ml) in EC-SOD null mice
(Fig. 3B). Therefore, EC-SOD, which is localized at high concentra-
tions in the pulmonary interstitium, attenuates hyaluronan release
into BALF following bleomycin-induced oxidative injury.) BALF samples from ﬁve mice for each exposure were combined and blotted onto a
-binding protein coupled with biotin and streptavidin-HRP. The HRP complex was
was measured using ELISA. Results shown are mean ± S.D.; *P < 0.01. (C) Effect of
EC-SOD KO mice were treated with saline or bleomycin. Seven days after exposure
luronan samples were separated on 1.2% agarose gel, transferred to nitrocellulose
in. Four mice were analyzed for saline treatment and ﬁve mice were analyzed for
Fig. 4. Effect of bleomycin exposure on hyaluronan synthases (HAS) expression in
the lung. Expression of HAS enzyme mRNA levels in the lungs of saline and
bleomycin treated wild-type and EC-SOD KO mice. Wild-type (WT) and EC-SOD KO
mice were exposed to saline (Sal) or bleomycin and the lung total RNA was puriﬁed
using Trizol seven days later. HAS1 (A), HAS2 (B) and HAS3 (C) mRNA levels were
analyzed using SYBR Green quantitative RT-PCR with gene speciﬁc primers. HAS
mRNA levels were normalized to b-actin mRNA levels. Results shown are
mean ± S.D.; *P < 0.05.
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before and after bleomycin exposure. Due to very low concentra-
tions of hyaluronan in BALF of untreated mice, the analysis of its
molecular size using available methods is problematic. However,
we were able to isolate hyaluronan from lung tissue and analyze
by agarose gel electrophoresis. This method provides a relatively
good estimation of hyaluronan molecular size and relative levels.
The intensity of hyaluronan-speciﬁc bands increased following ble-
omycin treatment (Fig. 3C). However, no signiﬁcant accumulation
of small molecular size fragments were observed. Instead, the in-
creased range of hyaluronan polymers were detected in the lung
of mice following bleomycin exposure. Thus, our in vitro data are
not fully supported by our in vivo data. One explanation for these
discrepancies between the in vitro and in vivo experiments might
be that only a relatively small part of hyaluronan in the lung tissue
undergoes depolymerization and release into alveolar space. It is
possible that our assay is not sensitive (or speciﬁc) enough to de-
tect differences in the levels of small molecular mass hyaluronan.
Indeed, we were unable to detect hyaluronan using this method
on our BALF samples even after bleomycin exposure, while the ELI-
SA assay was able to detect drastic increases in hyaluronan concen-
trations. Previous studies have shown that treatment of mice with
asbestos increased the range of hyaluronan molecular sizes with
no obvious accumulation of hyaluronan fragments [15].
3.4. Accumulation of hyaluronan in BALF after bleomycin treatment is
not due to its synthesis
The accumulation of hyaluronan in the alveolar ﬂuid following
bleomycin administration can be attributed to it increased
synthesis by hyaluronan synthases; HAS1, HAS2 and HAS3. We
analyzed mRNA levels of the HAS family of genes in both wild-
type and EC-SOD null mice exposed to saline or bleomycin
(Fig. 4). HAS1 and HAS3 did not show any increase in the expres-
sion following bleomycin exposure. HAS2 mRNAs were slightly
elevated in the lung of mice treated with bleomycin, but the
extent of HAS2 gene induction was small to explain the dramatic
increase of hyaluronan levels in the alveolar ﬂuid following bleo-
mycin exposure. However, it can explain, at least in part, elevated
levels of hyaluronan in the lung tissues. The elevated hyaluronan
levels in BALF of bleomycin treated mice can also be a product of
modiﬁed activities of hyaluronan catabolizing enzymes. We did
not analyze the hyaluronidase activities in our samples, but pre-
viously published result showed no differences in HYAL activities
between control and asbestos-treated mice [15]. Thus, accumulat-
ing evidence, obtained by us and other investigators, suggests
that the mechanism by which hyaluronan accumulates in alveolar
ﬂuid, following acute lung injury, is due to depolymerization by
oxidative stress and not due to its enhanced synthesis or enzy-
matic degradation.
In this study we investigated the molecular mechanism(s) of
EC-SOD dependent protection of lung from bleomycin-induced in-
jury. We found that following acute injury caused by bleomycin
intratracheal instillation, levels of EC-SODandhyaluronan increased
considerably in BALF. In addition, EC-SOD KO mice showed signiﬁ-
cantly increased lung injury and higher levels of hyaluronan in alve-
olar ﬂuid compared to wild-type littermates. It has been reported
that EC-SOD interacts with and protects many molecules located
in the extracellular matrix (including type I collagen [16] and synd-
ecan [17]) from oxidative-induced fragmentation and degradation.
It has also been demonstrated that EC-SOD protects hyaluronan
from asbestos induced fragmentation, which in turn attenuates
the development of lung inﬂammation [15]. Our data provide addi-
tional support for an important role of EC-SOD in protection of lung
from bleomycin-induced injury through attenuation of hyaluronan
release into alveolar ﬂuid. It is interesting to note that EC-SOD alsoaccumulated in the BALF following bleomycin exposure, andmostly
in its full-length form. This is in contrast to previously published
data that shows accumulation of mostly proteolyzed forms of EC-
SOD [14]. Taking into account that EC-SOD can bind to hyaluronan,
we speculate that accumulation of full-length EC-SOD was due, at
least in part, to a depolymerization of hyaluronan with subsequent
2952 I.N. Zelko, R.J. Folz / FEBS Letters 584 (2010) 2947–2952release of hyaluronan-boundprotein into the alveolar space, andnot
to EC-SOD proteolytic cleavage.
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